NANOV.OL Live signaler | Maksimer profitt med Getagraph.com

KJøP 445222 min ago

@ Kr.1.932

Utstedt: 5 jul 2023 @ 16:25

Avkastning: 0.00%

Live Chart Being Loaded With Signals

Commentary (5 jul 2023 @ 16:25):

Stats
Dagens volum	2.50M
Gjennomsnittsvolum	3.95M
Markedsverdi	451.20M
EPS	Kr.0 ( 2024-02-26 )
Last Dividend	Kr.0 ( N/A )
Next Dividend	Kr.0 ( N/A )
P/E	-0.826
ATR14	Kr.0.389 (20.16%)

Volum Korrelasjon

Lang: 0.78 (moderate)

Kort: 0.62 (weak)

Signal:(50.96) Neutral

Nordic Nanovector ASA Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Nordic Nanovector ASA Korrelasjon - Valuta/Råvare

0.77
( moderate )

0.56
( weak )

-0.14
( neutral )

0.23
( neutral )

0.59
( weak )

-0.69
( moderate negative )

Financial Reports:

No articles found.

Nordic Nanovector ASA

Nordic Nanovector ASA, a biopharmaceutical company, develops and commercializes therapeutics for hematological cancers in Norway. The company\'s lead product candidate is Betalutin, a CD37-targeting antibody-radionuclide-conjugate, which is in Phase 2b clinical trial for the treatment of patients with non-hodgkin lymphoma. Its preclinical development product also includes Alpha37, an anti-CD37 alphaparticle emitting radioimmunoconjugate for treating chronic lymphatic leukemia. The company has collaboration agreements with Paul Scherrer Institute; ArevaMed; LegoChem Bio; and Heidelberg Pharma. It also has a research collaboration with the University of Pennsylvania to generate a CD37-targeting CAR-T cell approach as a treatment for patients with B-cell malignancies. The company was formerly known as Nordic Nanovector AS and changed its name to Nordic Nanovector ASA in 2014. Nordic Nanovector ASA was incorporated in 2009 and is headquartered in Oslo, Norway.